Last updated: 02/15/2019 19:40:47
Special Drug Use Investigation of RELVAR® for Asthma patients
Clinicaltrials.gov ID
Not applicable
EudraCT ID
Not applicable
EU CT Number
Not applicable
Trial status
Finalized
Finalized
Trial overview
Official title: Special Drug Use Investigation of RELVAR® for Asthma patients
Trial description: This is a post-marketing surveillance (PMS) study conducted in Japan. The purpose of this investigation is to collect and assess information on the safety and effectiveness for long-term use of vilanterol trifenatate and fluticasone furoate in routine clinical practice. RELVAR is a registered trademark of the GSK group of companies.
Primary purpose:
Not applicable
Trial design:
Not applicable
Masking:
Not applicable
Allocation:
Not applicable
Primary outcomes:
Occurrence of adverse drug reactions and infections in routine clinical practice.
Timeframe: 1 year
Total scores of Athma Control Test
Timeframe: 1 year
Secondary outcomes:
Not applicable
Interventions:
Drug: Vilanterol trifenatate and fluticasone furoate
Enrollment:
1240
Observational study model:
Case-Only
Primary completion date:
2018-29-03
Time perspective:
Prospective
Clinical publications:
Hironori Sagara, Junko Minami, Naho Oyanagi, Isao Mukai, Akihiro Kobayashi, Terufumi Hara. Safety and effectiveness of vilanterol trifenatate / fluticasone furoate dry powder inhaler in patients with bronchial asthma in clinical practice: A report of 1-year special drug use investigation. Ther Res. 2018;39(11):935-952
Medical condition
Asthma
Product
fluticasone furoate, fluticasone furoate/vilanterol, vilanterol
Collaborators
Not applicable
Study date(s)
September 2014 to March 2018
Type
Observational
Phase
Not applicable
Participation criteria
Sex
Female & Male
Age
Not applicable
Accepts healthy volunteers
None
- Patients with asthma
- Patients who are treated with vilanterol trifenatate and fluticasone furoate for the first time, and expected for long-term use.
- None
Inclusion and exclusion criteria
Inclusion criteria:
- Patients with asthma
- Patients who are treated with vilanterol trifenatate and fluticasone furoate for the first time, and expected for long-term use.
Exclusion criteria:
- None
Trial location(s)
No location data available.
Study documents
Statistical analysis plan
Available language(s): English
Protocol
Available language(s): English
Scientific result summary
Available language(s): English
Clinical study report
Available language(s): English
If you wish to request for full study report, please contact - [email protected]
Results overview
Refer to study documents
Recruitment status
Finalized
Actual primary completion date
2018-29-03
Actual study completion date
2018-29-03
Plain language summaries
Not applicable. GSK’s transparency policy provides for Plain Language Summaries for Interventional studies.
Additional information about the trial
Not applicable
Participate in clinical trial
Access to clinical trial data by researchers
Visit website